David Krempa Sells 37,524 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 37,524 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $31.49, for a total value of $1,181,630.76. Following the completion of the transaction, the insider owned 25,249 shares in the company, valued at approximately $795,091.01. The trade was a 59.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total value of $619,298.13.

Eton Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ ETON opened at $31.86 on Friday. The stock has a market cap of $872.65 million, a PE ratio of -455.08 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. Eton Pharmaceuticals, Inc. has a 52-week low of $13.09 and a 52-week high of $35.66. The business has a 50-day moving average price of $26.85 and a 200 day moving average price of $20.14.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The firm had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. Equities research analysts forecast that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current year.

Institutional Trading of Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $74,000. Finally, SG Americas Securities LLC acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $109,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ETON has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. HC Wainwright upped their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Finally, Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.